Skip to main content
Themis Medicare Ltd. logo

Themis Medicare Ltd. — Investor Relations & Filings

Ticker · THEMISMED ISIN · INE083B01024 LEI · 335800LHRDVIKH69AF42 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2023-06-26 Regulatory Filings
Country IN India
Listing BSE.NS THEMISMED

About Themis Medicare Ltd.

https://www.themismedicare.com/

Themis Medicare Ltd. is a research-driven pharmaceutical organization specializing in the development, manufacture, and marketing of a diverse range of therapeutic products. The company focuses on high-value segments including pain management, anesthesia, critical care, anti-infectives, and oncology. Its core competencies lie in the production of Active Pharmaceutical Ingredients (APIs) and complex finished dosage formulations, particularly injectables. Themis Medicare maintains a strong emphasis on Research and Development, operating state-of-the-art facilities that adhere to international quality standards such as WHO-GMP. Through strategic partnerships and a robust supply chain, the company serves both domestic and international markets, providing specialized medical solutions for hospital-based care and chronic disease management. Its portfolio includes proprietary delivery systems and differentiated generic products designed to improve patient outcomes.

Recent filings

Filing Released Lang Actions
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding an intimation under regulation 39(3) of SEBI (LODR) Regulations, 2015. It informs about the receipt of a request for loss of share certificate and issuance of a duplicate share certificate for a shareholder. The content is about compliance and procedural update related to share certificates, not a financial report, earnings release, or management discussion. It is a regulatory compliance announcement related to shareholding records and does not fit into categories like Annual Report, Earnings Release, or Capital Update. It is not a report publication announcement since it is not about publishing a report but an official regulatory intimation. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short and focused on regulatory compliance.
2023-06-26 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2023-06-13 English
Annual Secretarial Compliance Report
Regulatory Filings Classification · 95% confidence The document is titled 'Revised Annual Secretarial Compliance Report for the Financial Year 2022-2023' and is issued by a practicing company secretary firm. It reviews compliance with statutory provisions and corporate governance practices for the financial year ended March 31, 2023. The content includes detailed compliance status with SEBI regulations, company secretarial standards, and other governance-related matters. It is a compliance report rather than a financial report or announcement. It is not an Annual Report (10-K), Audit Report (AR), or any financial statement. It is also not a simple announcement or certification but a detailed compliance report by company secretaries. This fits the category of Regulatory Filings (RNS) as it is a regulatory compliance report submitted to stock exchanges under SEBI regulations, and does not fall under other more specific categories like Annual Report or Management Reports. The document length (15,000 characters) and detailed content confirm it is a full compliance report, not just an announcement or certification.
2023-05-31 English
Annual Secretarial Compliance Report
Regulatory Filings
2023-05-27 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding an intimation under regulation 39(3) of SEBI (LODR) Regulations, 2015. It informs about the loss of share certificates and issuance of duplicate share certificates for a shareholder. The content is a compliance notification related to share certificate management and does not contain financial data, management discussion, or report publication. It is a regulatory compliance filing notifying the exchange about a shareholder's request for duplicate share certificates. The document length is 3225 characters, which is relatively short and focused on regulatory compliance. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a financial report or other specific filing type.
2023-05-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of a conference call held on May 15, 2023, discussing the Q4 and full fiscal year 2023 financial results of Themis Medicare Limited. It includes detailed management commentary on business segments, financial performance, future outlook, and a Q&A session with analysts and investors. The presence of a moderator, management speakers, and Q&A format confirms it is a call transcript. The document references the earnings conference call and provides detailed financial figures and operational updates, which are typical of earnings call transcripts. Therefore, the document fits the category of a Call Transcript (CT).
2023-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.